Global Specimen Solutions, Inc. Closes Series A Funding

GSS Builds Momentum for Specialty Specimen CRO Services and Infrastructure

Cary, North Carolina. – Global Specimen Solutions, Inc. (, an innovative specialty CRO focused on specimen management and informatics, announced today that Series A funding was closed.

“Global Specimen Solutions, Inc. is excited to catapult our growing momentum in clinical specimen management with investment that will further enhance our proprietary informatics tools and infrastructure to build our first-to-market services supporting specimen research. GSS has proved rapid market uptake of our clinical trial management services and products for translational medicine, and this funding will help speed introduction of new proprietary tools to our growing client base.” –Amelia Wall Warner, Founder and CEO

Dr. Warner launched Global Specimen Solutions, Inc. in July of 2013 with innovative services not offered by other CROs or specialty providers.  Taking her years of experience at Merck, Schering-Plough, Wyeth, and the Children’s Hospital of Philadelphia, Dr. Warner built GSS with research in mind.

“Understanding how researchers need to use specimens and datasets for ongoing support of clinical development programs, research collaborations, and discovery research efforts informed how GSS built its model.  With our expertise in clinical trial service, we integrated compliant processes and informatics that supported high collection rates, broad consent, detailed in-life annotation, and expert data curation into our approach.  This sets us apart from others in the clinical trial space that focus on other aspects of clinical trial management.”-Amelia Wall Warner, Founder and CEO.

Dr. Warner was Head of Clinical Pharmacogenomics and Clinical Specimen Management at Merck where she was responsible for one of the largest collections of specimens for research in the world.  She is a past chair of the Industry Pharmacogenomics Working Group (I-PWG) and was a PhRMA representative to ICH E16- Genomic Biomarkers Related to Drug Response.  As an industry expert, she has participated in numerous meetings and conferences as a key opinion leader on applying pharmacogenomics in drug development, best practices for collecting, maintaining, and maximizing return-on-investment for clinical sample biobanks in all phases of clinical trials, and appropriate informed consent to enable future use and testing. Dr. Warner brings to Global Specimen Solutions, Inc. this cutting edge clinical and regulatory expertise that will ultimately provide clients with the most up-to-date framework for integrating pharmacogenomics into their drug development programs.

Dr. Warner completed a residency in Pediatric Pharmacotherapy at St. Jude Children’s Research Hospital with John Rodman, PharmD and a fellowship in Clinical Pharmacology/ Pharmacogenomics at St. Jude Children’s Research Hospital with William Evans, PharmD. Amelia holds a PharmD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Biology from Wake Forest University.

About Global Specimen Solutions, Inc.:

Founded in 2013, Global Specimen Solutions, Inc. is located in Cary, NC, where it provides pharmacogenomics and biorepository operational support for all phases of clinical studies and genomic biomarker programs.  The Company works with academic and industry leaders to assure real-time collection, compliance, and usage of human specimens for research. Pharmacogenomic and biomarker research will result in development of safer, more effective medicines, enhance in-life drug development decisions, and improve patient medical treatment globally.

Media Contact:
Amelia Wall Warner, PharmD, RPh
CEO, Founder
Global Specimen Solutions, Inc.